Elanco Animal Health is making progress on debt repayment, new product approvals, and launches. Learn why ELAN stock is a Buy ...

Rosenberg Matthew Hamilton cut its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 45.5% in the 4th quarter, ...

Librela is the first mAb the FDA has approved for use in dogs. Also Read: Animal Health-Focused Zoetis Stock Faces Near-Term Pressure, Analyst Cites Uncertainty In Q4 Results, Weak Margins.

Stifel lowered the firm’s price target on Zoetis (ZTS) to $180 from $210 and keeps a Buy rating on the shares. 2024 was a “tough year” for ...

Parsippany, NJ-based Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. The entity started trading on the NYSE on Feb 1, 2013, under the name Zoetis.

In a report released on January 9, Daniel Clark from Leerink Partners reiterated a Buy rating on Zoetis (ZTS – Research Report), with a price ...

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 13, 2025. Chief ...

Investment analysts at Zacks Research cut their FY2025 earnings estimates for Zoetis in a research report issued on Wednesday ...

Zoetis Background Information (This description is provided by the company.) Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on ...

Zoetis, Inc. engages in the discovery ... genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments.

animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000 ...